RhumbLine Advisers
ADPT icon

RhumbLine Advisers’s Adaptive Biotechnologies ADPT Stock Holding History

RhumbLine Advisers’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.28M Buy
199,336
+16,464
+9% +$252K ﹤0.01% 1551
2026
Q1 		$2.54M Sell
182,872
-1,764
-1% -$28.1K ﹤0.01% 1737
2025
Q4 		$3M Sell
184,636
-19,307
-9% -$315K ﹤0.01% 1660
2025
Q3 		$3.05M Sell
203,943
-6,058
-3% -$73.8K ﹤0.01% 1676
2025
Q2 		$2.45M Buy
210,001
+21,477
+11% +$195K ﹤0.01% 1779
2025
Q1 		$1.4M Buy
188,524
+7,322
+4% +$56.3K ﹤0.01% 2005
2024
Q4 		$1.09M Buy
181,202
+5,361
+3% +$29.6K ﹤0.01% 2214
2024
Q3 		$900K Sell
175,841
-12,444
-7% -$54.2K ﹤0.01% 2317
2024
Q2 		$682K Buy
188,285
+14,430
+8% +$45.8K ﹤0.01% 2452
2024
Q1 		$558K Buy
173,855
+4,290
+3% +$16.6K ﹤0.01% 2604
2023
Q4 		$831K Buy
169,565
+9,346
+6% +$42.6K ﹤0.01% 2366
2023
Q3 		$873K Buy
160,219
+2,969
+2% +$19.6K ﹤0.01% 2286
2023
Q2 		$1.06M Sell
157,250
-20,947
-12% -$156K ﹤0.01% 2255
2023
Q1 		$1.57M Buy
178,197
+6,183
+4% +$54.5K ﹤0.01% 1930
2022
Q4 		$1.31M Buy
172,014
+1,550
+0.9% +$12.1K ﹤0.01% 2005
2022
Q3 		$1.21M Buy
170,464
+10,091
+6% +$95K ﹤0.01% 2036
2022
Q2 		$1.3M Buy
160,373
+64,121
+67% +$564K ﹤0.01% 2008
2022
Q1 		$1.34M Sell
96,252
-6,976
-7% -$110K ﹤0.01% 2007
2021
Q4 		$2.9M Buy
103,228
+4,739
+5% +$145K ﹤0.01% 1694
2021
Q3 		$3.35M Sell
98,489
-1,329
-1% -$48.1K ﹤0.01% 1596
2021
Q2 		$4.08M Buy
99,818
+23,136
+30% +$899K 0.01% 1530
2021
Q1 		$3.09M Sell
76,682
-9,246
-11% -$500K ﹤0.01% 1677
2020
Q4 		$5.08M Buy
85,928
+1,928
+2% +$99.4K 0.01% 1348
2020
Q3 		$4.08M Buy
84,000
+3,775
+5% +$159K 0.01% 1289
2020
Q2 		$3.88M Buy
80,225
+20,179
+34% +$736K 0.01% 1354
2020
Q1 		$1.67M Buy
60,046
+44,386
+283% +$1.24M ﹤0.01% 1639
2019
Q4 		$469K Buy
15,660
+4,291
+38% +$123K ﹤0.01% 2389
2019
Q3 		$351K Buy
+11,369
New +$464K ﹤0.01% 2493

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

RhumbLine Advisers's ADPT Position: Q2 2026 in Review

RhumbLine Advisers increased its Adaptive Biotechnologies (ADPT) stake by 9% in Q2 2026, buying an estimated $252K and bringing the position to 199,336 shares worth $4.28M. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

RhumbLine Advisers first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $5.08M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • RhumbLine Advisers held 199,336 shares of Adaptive Biotechnologies worth $4.28M as of Q2 2026.
  • RhumbLine Advisers bought 16,464 Adaptive Biotechnologies shares in Q2 2026, an estimated $252K.
  • Adaptive Biotechnologies made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1551 holding.
  • RhumbLine Advisers first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • RhumbLine Advisers's Adaptive Biotechnologies position peaked at $5.08M in Q4 2020.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.